Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes

Citations Over TimeTop 22% of 2013 papers

Abstract

Standard glucose-lowering therapeutic agents demonstrated significant acute glucose lowering in male gk(wt/del) mice at doses corresponding to therapeutic free drug levels in man, suggesting the potential of these mice as a translatable model of human T2D. Novel GKAs also lowered glucose in this mouse model.

Related Papers

• → Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial(2007)663 cited
• → Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study(2010)202 cited
• → The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus(2011)90 cited
• → Glycemic Control by Combination Therapy of Sitagliptin-Metformin Versus Metformin Alone(2020)1 cited
• → Efficacy of Dapagliflozin & Metformin Vs Sitagliptin & Metformin in New patients with Type 2 Diabetic in HMC Hospital Peshawar(2022)